Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas

Detalhes bibliográficos
Autor(a) principal: Gales, Ana Cristina [UNIFESP]
Data de Publicação: 1997
Outros Autores: Pignatari, Antonio Carlos Campos [UNIFESP], Jones, R.n. [UNIFESP], Baretta, M. [UNIFESP], Sader, Helio Silva [UNIFESP]
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1590/S0104-42301997000200010
http://repositorio.unifesp.br/handle/11600/492
Resumo: OBJECTIVE. Evaluation of the in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against gram-negative bacteria. MATERIAL AND METHOD. A total of 569 clinical isolates were obtained from inpatients at São Paulo Hospital - UNIFESP/EPM in June and July of 1992. The species distribution was as follows: Enterobacter sp. (62), Escherichia coli (308), Klebsiella pneumoniae (27), Klebsiella sp. (9), Proteus mirabilis (23), Pseudomonas aeruginosa (88), Pseudomonas sp. (4), Serratia sp. (30) and other gram-negatives (7). Susceptibility tests were performed by broth microdilution. The antimicrobials agents tested were: ciprofloxacin, ofloxacin, levofloxacin, grepafloxacin, DU 6859-a, ceftazidime, cefepime, FK 037, imipenem, meropenem and biapenem. RESULTS. DU 6859-a showed the highest antimicrobial activity among the fluoroquinolones. It was two- to four-fold more active than ciprofloxacin against some species. The potency and antimicrobial spectrum were similar between the fourth-generation cephalosporins against Enterobacteriaceae, except for Enterobacter sp. strains which were more susceptible to cefepime than they were to cefetazidime or FK 037. When testing Pseudomonas aeruginosa, ceftazidime was slightly more active than the other cephalosporins. Against Enterobacteriaceae and Pseudomonas aeruginosa strains, meropenem was more active than imipenem or biapenem. In addition, the percentage of strains, susceptible to meropenem was higher than the percentage susceptible to the other cerbapenems against these species. CONCLUSION. The new antimicrobial agents demonstrated in vitro activity higher than that of agents commercially avaliable. However, more studies are necessary to further evaluate the in vivo activity and the clinical benefit of these compounds.
id UFSP_b215606eebab8cba6ca93b067e99d11d
oai_identifier_str oai:repositorio.unifesp.br/:11600/492
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativasEvaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 gram-negative bacteriaIn vitro activityGram-negative bacteriaFluoroquinolonesCephalosporinsCarbapenemsAtividade in vitroBactérias gram-negativasFluoroquinolonasCefalosporinasCarbapenensOBJECTIVE. Evaluation of the in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against gram-negative bacteria. MATERIAL AND METHOD. A total of 569 clinical isolates were obtained from inpatients at São Paulo Hospital - UNIFESP/EPM in June and July of 1992. The species distribution was as follows: Enterobacter sp. (62), Escherichia coli (308), Klebsiella pneumoniae (27), Klebsiella sp. (9), Proteus mirabilis (23), Pseudomonas aeruginosa (88), Pseudomonas sp. (4), Serratia sp. (30) and other gram-negatives (7). Susceptibility tests were performed by broth microdilution. The antimicrobials agents tested were: ciprofloxacin, ofloxacin, levofloxacin, grepafloxacin, DU 6859-a, ceftazidime, cefepime, FK 037, imipenem, meropenem and biapenem. RESULTS. DU 6859-a showed the highest antimicrobial activity among the fluoroquinolones. It was two- to four-fold more active than ciprofloxacin against some species. The potency and antimicrobial spectrum were similar between the fourth-generation cephalosporins against Enterobacteriaceae, except for Enterobacter sp. strains which were more susceptible to cefepime than they were to cefetazidime or FK 037. When testing Pseudomonas aeruginosa, ceftazidime was slightly more active than the other cephalosporins. Against Enterobacteriaceae and Pseudomonas aeruginosa strains, meropenem was more active than imipenem or biapenem. In addition, the percentage of strains, susceptible to meropenem was higher than the percentage susceptible to the other cerbapenems against these species. CONCLUSION. The new antimicrobial agents demonstrated in vitro activity higher than that of agents commercially avaliable. However, more studies are necessary to further evaluate the in vivo activity and the clinical benefit of these compounds.OBJETIVO. A proposta deste estudo foi a avaliação da atividade in vitro de novos antimicrobianos da classe das fluoroquinolonas, das cefalosporinas e dos carbapenens contra bactérias gram-negativas. MATERIAL E MÉTODO. Foram avaliadas 569 amostras clínicas isoladas no Hospital São Paulo - UNIFESP/EPM, no período compreendido entre junho e julho de 1992. A distribuição das espécies foi: Enterobacter sp. (62), Escherichia coli (308), Klebsiella pneumoniae (27), Klebsiella sp. (9), Proteus mirabilis (23), Pseudomonas aeruginosa (88), Pseudomonas sp. (4), Serratia sp. (30) e outros gram-negativos (7). Os testes de sensibilidade aos antimicrobianos avaliados (ciprofloxacina, ofloxacina, levofloxacina, grepafloxacina, DU 6859-a, ceftazidima, cefepima, FK 037, imipenem, meropenem e biapenem) foram realizados pela técnica de microdiluição em caldo. RESULTADOS. A fluoroquinolona mais potente foi a DU 6859-a; em algumas amostras, apresentou potência duas a quatro vezes superior àquela apresentada pela ciprofloxacina. As novas cefalosporinas de 4ª geração apresentaram potência e espectro de ação semelhantes nas amostras de Enterobacteriaceae, com exceção das amostras de Enterobacter sp., para as quais a cefepima foi mais ativa, e das amostras de P. aeruginosa, para as quais a cefalosporina mais potente e com maior percentagem de suscetibilidade foi a ceftazidima. O meropenem foi o carbapenem mais potente e com maior percentagem de suscetibilidade nas amostras estudadas. CONCLUSÃO. As novas drogas apresentaram, em geral, melhor atividade in vitro do que drogas da mesma classe já utilizadas na prática clínica. Porém, mais estudos serão necessários para avaliar a atividade in vivo desses agentes e sua real utilidade clínica.Universidade Federal de São Paulo (UNIFESP) Escola Paulista de Medicina Laboratório Especial de Microbiologia ClínicaUNIFESP, EPM, Laboratório Especial de Microbiologia ClínicaSciELOAssociação Médica BrasileiraUniversidade Federal de São Paulo (UNIFESP)Gales, Ana Cristina [UNIFESP]Pignatari, Antonio Carlos Campos [UNIFESP]Jones, R.n. [UNIFESP]Baretta, M. [UNIFESP]Sader, Helio Silva [UNIFESP]2015-06-14T13:24:36Z2015-06-14T13:24:36Z1997-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion137-144application/pdfhttp://dx.doi.org/10.1590/S0104-42301997000200010Revista da Associação Médica Brasileira. Associação Médica Brasileira, v. 43, n. 2, p. 137-144, 1997.10.1590/S0104-42301997000200010S0104-42301997000200010.pdf0104-4230S0104-42301997000200010http://repositorio.unifesp.br/handle/11600/492porRevista da Associação Médica Brasileirainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-06T03:26:14Zoai:repositorio.unifesp.br/:11600/492Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-06T03:26:14Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas
Evaluation of in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against 569 gram-negative bacteria
title Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas
spellingShingle Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas
Gales, Ana Cristina [UNIFESP]
In vitro activity
Gram-negative bacteria
Fluoroquinolones
Cephalosporins
Carbapenems
Atividade in vitro
Bactérias gram-negativas
Fluoroquinolonas
Cefalosporinas
Carbapenens
title_short Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas
title_full Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas
title_fullStr Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas
title_full_unstemmed Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas
title_sort Avaliação da atividade in vitro dos novos antimicrobianos da classe das fluoroquinolonas, cefalosporinas e carbapenens contra 569 amostras clínicas de bactérias gram-negativas
author Gales, Ana Cristina [UNIFESP]
author_facet Gales, Ana Cristina [UNIFESP]
Pignatari, Antonio Carlos Campos [UNIFESP]
Jones, R.n. [UNIFESP]
Baretta, M. [UNIFESP]
Sader, Helio Silva [UNIFESP]
author_role author
author2 Pignatari, Antonio Carlos Campos [UNIFESP]
Jones, R.n. [UNIFESP]
Baretta, M. [UNIFESP]
Sader, Helio Silva [UNIFESP]
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Gales, Ana Cristina [UNIFESP]
Pignatari, Antonio Carlos Campos [UNIFESP]
Jones, R.n. [UNIFESP]
Baretta, M. [UNIFESP]
Sader, Helio Silva [UNIFESP]
dc.subject.por.fl_str_mv In vitro activity
Gram-negative bacteria
Fluoroquinolones
Cephalosporins
Carbapenems
Atividade in vitro
Bactérias gram-negativas
Fluoroquinolonas
Cefalosporinas
Carbapenens
topic In vitro activity
Gram-negative bacteria
Fluoroquinolones
Cephalosporins
Carbapenems
Atividade in vitro
Bactérias gram-negativas
Fluoroquinolonas
Cefalosporinas
Carbapenens
description OBJECTIVE. Evaluation of the in vitro activity of new fluoroquinolones, cephalosporins and carbapenems against gram-negative bacteria. MATERIAL AND METHOD. A total of 569 clinical isolates were obtained from inpatients at São Paulo Hospital - UNIFESP/EPM in June and July of 1992. The species distribution was as follows: Enterobacter sp. (62), Escherichia coli (308), Klebsiella pneumoniae (27), Klebsiella sp. (9), Proteus mirabilis (23), Pseudomonas aeruginosa (88), Pseudomonas sp. (4), Serratia sp. (30) and other gram-negatives (7). Susceptibility tests were performed by broth microdilution. The antimicrobials agents tested were: ciprofloxacin, ofloxacin, levofloxacin, grepafloxacin, DU 6859-a, ceftazidime, cefepime, FK 037, imipenem, meropenem and biapenem. RESULTS. DU 6859-a showed the highest antimicrobial activity among the fluoroquinolones. It was two- to four-fold more active than ciprofloxacin against some species. The potency and antimicrobial spectrum were similar between the fourth-generation cephalosporins against Enterobacteriaceae, except for Enterobacter sp. strains which were more susceptible to cefepime than they were to cefetazidime or FK 037. When testing Pseudomonas aeruginosa, ceftazidime was slightly more active than the other cephalosporins. Against Enterobacteriaceae and Pseudomonas aeruginosa strains, meropenem was more active than imipenem or biapenem. In addition, the percentage of strains, susceptible to meropenem was higher than the percentage susceptible to the other cerbapenems against these species. CONCLUSION. The new antimicrobial agents demonstrated in vitro activity higher than that of agents commercially avaliable. However, more studies are necessary to further evaluate the in vivo activity and the clinical benefit of these compounds.
publishDate 1997
dc.date.none.fl_str_mv 1997-06-01
2015-06-14T13:24:36Z
2015-06-14T13:24:36Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/S0104-42301997000200010
Revista da Associação Médica Brasileira. Associação Médica Brasileira, v. 43, n. 2, p. 137-144, 1997.
10.1590/S0104-42301997000200010
S0104-42301997000200010.pdf
0104-4230
S0104-42301997000200010
http://repositorio.unifesp.br/handle/11600/492
url http://dx.doi.org/10.1590/S0104-42301997000200010
http://repositorio.unifesp.br/handle/11600/492
identifier_str_mv Revista da Associação Médica Brasileira. Associação Médica Brasileira, v. 43, n. 2, p. 137-144, 1997.
10.1590/S0104-42301997000200010
S0104-42301997000200010.pdf
0104-4230
S0104-42301997000200010
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv Revista da Associação Médica Brasileira
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 137-144
application/pdf
dc.publisher.none.fl_str_mv Associação Médica Brasileira
publisher.none.fl_str_mv Associação Médica Brasileira
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268407103619072